Accustem Sciences Inc.

Accustem Sciences Inc. is a clinical stage diagnostics company focused on developing and commercializing genomic tests for cancer patients. The company aims to offer a suite of novel genomic tests to support decision-making across oncology care. Its initial commercialization efforts will focus on the US market, which it estimates represents more than $6.3 billion in annual revenue. The company's primary proprietary genomic tests are MSC (MicroRNA Signature Classifier) and StemPrintER. The MSC test is a 24-micro RNA (miRNA) assay designed to help determine if lung nodules, identified by LDCT (low dose computer tomography) screening, are benign or malignant. This test aims to minimize overtreatment and undertreatment for the 1.6 million patients diagnosed with lung nodules annually in the US, and to reduce healthcare costs by improving the accuracy of LDCT alone. MSC has been validated in multiple prospective, randomized cohorts involving over 5,000 patients and published in the Journal of Clinical Oncology. StemPrintER is a 20-gene prognostic assay intended to predict the risk of distant recurrence ("DR") in luminal (ER+/HER2-negative) breast cancer patients. This assay measures the "stemness" of tumors, which can indicate the likelihood of cancer recurrence or resistance to standard treatments. StemPrintER has been validated in more than 3,000 patients across multiple clinical cohorts, including the TransATAC study. These data confirm StemPrintER's prognostic value for outcomes in breast cancer patients.